NCT06052566

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Efinopegdutide (MK-6024) in Participants With Moderate and Severe Hepatic Impairment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study was to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.

Conditions

• Non-alcoholic Steatohepatitis
• Hepatic Impairment

Interventions

Type	Name	Description
DRUG	Efinopegdutide	Subcutaneous injection administered at a dose of 7 mg

Timeline

• Start date: 2023-11-21
• Primary completion: 2024-12-05
• Completion: 2024-12-05
• First posted: 2023-09-25
• Last updated: 2025-10-22
• Results posted: 2025-10-22

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study